Major depressive disorder (MDD), commonly referred to as depression, is a serious medical condition that affects a person's ...

Cassava Sciences stock plummeted Monday — wiping out more than three-quarters of its value — after the company's Alzheimer's treatment failed in Phase 3 testing. Please watch the video at ...

Highlights:,Biogen Inc. (BIIB) has underperformed the broader market and key healthcare ETFs in recent years.,The company’s ...

Cambridge, Massachusetts-based Biogen Inc. ( BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

Jefferies analyst Michael Yee maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $250.00. The company’s shares opened today at $159.99. Don't Miss our Black ...

Biogen (NASDAQ:BIIB – Free Report) had its price objective decreased by Mizuho from $251.00 to $207.00 in a research note published on Thursday,Benzinga reports. Mizuho currently has an outperform ...

The S&P500 (SP500) closed in the green on Friday, with companies including Walmart, Nvidia and Gap stealing the limelight ...

Needham has recently reduced Biogen Inc (BIIB) stock to Hold rating, as announced on November 18, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had initiated the stock to ...

The firm is also studying PTG-007 in patients with early-stage type 1 diabetes, but is looking for a partner for the pivotal trial.

In this piece, we will look at where Biogen Inc. (NASDAQ:BIIB) ranks on the list. With the 2024 US Presidential Election ...

Needham has recently reduced Biogen Inc (BIIB) stock to Hold rating, as announced on November 18, 2024, according to Finviz. Earlier, on November 15, 2024, Wolfe Research had initiated the stock to ...

Dapirolizumab pegol was better than a placebo at controlling disease activity in systemic lupus erythematosus patients in a Phase 3 trial.